- Visibility 94 Views
- Downloads 63 Downloads
- Permissions
- DOI 10.18231/pjms.v.15.i.2.312-318
-
CrossMark
- Citation
Comparison of cisplatin doublet therapy in non-small cell lung cancer
- Author Details:
-
Mohammed Danish
-
Huma Firdaus
-
Nafees Ahmad Khan *
Introduction: Patients with lung cancer may be eligible for a variety of therapies, including surgery, radiation, chemotherapy, and targeted therapy, depending on their stage. Specific mutations have been identified thanks to breakthroughs in genetics and biomarker testing, allowing for more personalised treatment for particular patients. Nearly 40% of lung cancer patients who are newly diagnosed are in stage IV. The first-line treatment for stage IV non-small cell lung cancer is cytotoxic combination chemotherapy, which is determined by histology, performance status, and age vs. comorbidities. The American Society of Clinical Oncology recommends a platinum (cisplatin or carboplatin) with paclitaxel, gemcitabine, vinorelbine, docetaxel, pemetrexed, or irinotecan regimen.
Material and Methods: this study was done on 40 patients of non-small cell cancer who were divided into two groups of 20 patients each. One group was given cisplatin and paclitaxel while other was given cisplatin and gemcitabine. 32 male and 8 female patients in the age group 47-83 years were included in the study to compare and see the difference in overall survival and toxicity in two groups.
Result: overall survival in gemcitabine group was found to be 8.75 months and in paclitaxel group was found to be 8.05 months. Toxicities were found to be higher in gemcitabine group.
Conclusion: average overall survival was higher in gemcitabine group however it was not statistically significant from the other group. Toxicities were also found to be higher in gemcitabine group. Further larger studies are required to find a statistical significant conclusion.
References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
- Mohan A, Latifi AN, Guleria R. Increasing incidence of adenocarcinoma lung in India: Following the global trend?. Indian J Cancer. 2016;53(1):92–5.
- Singh N, Aggarwal AN, Gupta D, Behera D, Jindal SK. Quantified smoking status and non-small cell lung cancer stage at presentation: analysis of a North Indian cohort and a systematic review of literature. J Thoracic Dis. 2012;4(5):474–84.
- Minna, JD; Schillar JH. Harrison’s Principles of Internal Medicine (17th Ed.). McGraw Hill. 2008:551–62
- Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol. 1988;6(4):633-41.
- Cullen M, Billingham J, Woodraffe C, Chetiyawardana AD, Gower NH, Joshi R, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999;17(10):3188–94
- Sandler AB, Ansari R, McClean J, Fisher W, Dorr A, Einhorn LH. A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer. InProc Am Soc Clin Oncol. 1995;14:357.
- Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. 1086 A phase II study of gemcitabine with cisplatin in patients with non-small cell lung cancer. Eur J Cancer. 1995;31:S226.
- Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, et al. Cisplatin-gemcitabine combination in advanced non-small- cell lung cancer: a phase II study. J Clin Oncol. 1997;15(1):297–
- Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995;13(8):1860–70.
- Le Chevalier T, Belli L, Monnier A, et al. Phase II study of docetaxel (Taxotere) and cisplatin in advanced non small cell lung cancer (NSCLC): an interim analysis. Prog Proc Am Soc Clin Oncol. 1995;14:350.
- Lilenbaum RC, Herndon J, List M et al. Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol. 2002;21:1a
- Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non–small-cell lung cancer: a meta-analysis. JAMA. 2004;292(4):470–84.
- Federal Drug Administration. Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville, MD: US Department of Health and Human Services; 2007
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–56.
- Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. New Engl J Med. 2002;346(2):92–8.
- Aisner J, Hansen HH. Current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep. 1981;65(11-12):979–86.
- Gatzemeier U, von Pawel J, Gottfried M, Velde GT, Mattson K, DeMarinis F, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non–small-cell lung cancer. J Clin Oncol. 2000;18(19):3390–9.
How to Cite This Article
Vancouver
Danish M, Firdaus H, Khan NA. Comparison of cisplatin doublet therapy in non-small cell lung cancer [Internet]. Panacea J Med Sci. 2025 [cited 2025 Oct 27];15(2):312-318. Available from: https://doi.org/10.18231/pjms.v.15.i.2.312-318
APA
Danish, M., Firdaus, H., Khan, N. A. (2025). Comparison of cisplatin doublet therapy in non-small cell lung cancer. Panacea J Med Sci, 15(2), 312-318. https://doi.org/10.18231/pjms.v.15.i.2.312-318
MLA
Danish, Mohammed, Firdaus, Huma, Khan, Nafees Ahmad. "Comparison of cisplatin doublet therapy in non-small cell lung cancer." Panacea J Med Sci, vol. 15, no. 2, 2025, pp. 312-318. https://doi.org/10.18231/pjms.v.15.i.2.312-318
Chicago
Danish, M., Firdaus, H., Khan, N. A.. "Comparison of cisplatin doublet therapy in non-small cell lung cancer." Panacea J Med Sci 15, no. 2 (2025): 312-318. https://doi.org/10.18231/pjms.v.15.i.2.312-318